Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;25(11-12):e202400109.
doi: 10.1002/pmic.202400109. Epub 2025 Jan 31.

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

Paul Perco  1   2 , Matthias Ley  1   3 , Kinga Kęska-Izworska  1 , Dorota Wojenska  1 , Enrico Bono  1   3 , Samuel M Walter  1 , Lucas Fillinger  1 , Klaus Kratochwill  1   3
Affiliations

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

Paul Perco et al. Proteomics. 2025 Jun.
No abstract available

Keywords: bioinformatics; biomedicine; heart disease; renal disease; systems biology; vascular disease.

PubMed Disclaimer

Conflict of interest statement

Paul Perco, Matthias Ley, Kinga Kęska‐Izworska, Dorota Wojenska, Enrico Bono, Samuel M. Walter, and Lucas Fillinger are employees of Delta 4 GmbH. Klaus Kratochwill is co‐founder of Delta4 GmbH.

Figures

FIGURE 1
FIGURE 1
Overview on drug repositioning approaches.
FIGURE 2
FIGURE 2
Challenges on the way to a new approved repurposed drug.
FIGURE 3
FIGURE 3
Running Phase III clinical trials in the cardiorenal space testing compounds approved for other indications. Running Phase III clinical trials for kidney diseases (A), heart diseases (B), and vascular diseases (C) testing compounds initially approved for different indications. Colors indicate the number of trials for a disease–drug pair. Bar plots at the top and to the right of the heatmaps show the sum of trials for a drug or disease, respectively. Drugs are ordered from left to right by the number of trials in decreasing order. Diseases are grouped based on MeSH hierarchy as schematically indicated by the dendrograms to the right.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mucke H. A. M., “COVID‐19 and the Drug Repurposing Tsunami,” Assay and Drug Development Technologies 18 (2020): 211–214. - PubMed
    1. Nosengo N., “Can You Teach Old Drugs New Tricks?” Nature 534 (2016): 314–316. - PubMed
    1. Neuberger A., Oraiopoulos N., and Drakeman D. L., “Renovation as Innovation: Is Repurposing the Future of Drug Discovery Research?” Drug Discovery Today 24 (2019): 1–3. - PubMed
    1. Jonker A. H., O'connor D., and Cavaller‐Bellaubi M., “Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community,” Frontiers in Medicine 11 (2024): 1352803. - PMC - PubMed
    1. Southall N. T., Natarajan M., and Lau L. P. L., “The Use or Generation of Biomedical Data and Existing Medicines to Discover and Establish New Treatments for Patients With Rare Diseases—Recommendations of the IRDiRC Data Mining and Repurposing Task Force,” Orphanet Journal of Rare Diseases 14 (2019): 225. - PMC - PubMed

LinkOut - more resources